- Economy
- Education And Career
- Companies & Markets
- Gadgets & Technology
- After Hours
- Healthcare
- Banking & Finance
- Entrepreneurship
- Energy & Infra
- Case Study
- Video
- More
- Sustainability
- Web Exclusive
- Opinion
- Luxury
- Legal
- Property Review
- Cloud
- Blockchain
- Workplace
- Collaboration
- Developer
- Digital India
- Infrastructure
- Work Life Balance
- Test category by sumit
- Sports
- National
- World
- Entertainment
- Lifestyle
- Science
- Health
- Tech
Latest Articles in novartis
Can We Afford This Wave?
People too are tired of all the restrictions, the loss of wages, loss of esteem and fatigue. More than 50% of the cases have originated in Maharashtra and its cities, defying normal logic.
Read More
Novartis Arthritis Drug Fails To Help COVID-19 Patients
The medicine, approved as Ilaris for juvenile arthritis and other conditions, also did not meet its key secondary endpoint of reducing COVID-19 mortality in a late-phase clinical trial
Read More
Novartis Arthritis Drug Fails To Help COVID-19 Patients
The medicine, approved as Ilaris for juvenile arthritis and other conditions, also did not meet its key secondary endpoint of reducing COVID-19 mortality in a late-phase clinical trial
Read More
Novartis Buys Vedere Bio, Whose Founders Helped Blind Mice See
Novartis is paying $150 million upfront for the U.S. biotechnology company, with the remainder in milestone payments for a total of $280 million.
Read More
Novartis Third-Quarter Core Net Income Rises To $3.47 Billion
The Basel-based company broadened its core operating income growth forecast to low double-digit to mid-teen percentage rate growth, from a low double-digit range previously, while net sales are expected to grow in the mid-single-digit percentage range.
Read More
Novartis Says Beovu Matched Rival Eylea In Visual Acuity In Eye Disease
"This data confirms our strong belief in Beovu as a potential therapy for DME patients," said Dirk Sauer, who leads Novartis Pharma Ophthalmology's drug development.
Read More
Roche Studies Ocrevus, Experimental Drug In MS As Novartis Moves In
Roche has started a late-stage clinical trial for its molecule fenebrutinib and is doing a clinical trial of higher-dose Ocrevus against relapsing MS and primary progressive MS.
Read More
Novartis Immuno-Oncology Drug Candidate Fails Skin Cancer Trial
The drug did not improve progression-free survival in previously untreated patients with BRAF V600 mutation-positive cutaneous melanoma, compared to Tafinlar + Mekinist alone, Novartis said.
Read More
Novartis To Provide 'No Profit' COVID-19 Drugs To Low-Income Countries
Novartis said it would provide medicines ranging from antibiotics and steroids to diarrhea pills to 79 countries on the World Bank's list of low- and lower-middle income nations.
Read More
Japan's Takeda Expects $200 Million Operating Loss Related To Novartis' Xiidra Withdrawal
Takeda sold Xiidra to Novartis for $3.4 billion upfront and up to an additional $1.9 billion in potential milestone receipts.
Read More
Novartis, Former Unit To Pay $346 Million To Resolve US Bribery Charges
Novartis will also pay $112.8 million to settle related civil charges by the U.S. Securities and Exchange Commission.
Read More
Novartis CEO Says Any New Coronavirus Vaccine Will Take Two Years
But experts have said no vaccine is expected to be ready for use until at least 2021, as they must be widely tested in humans before being administered to hundreds of millions, if not billions, of people to prevent infection.
Read More
Novartis Wins Expanded European OK For Cosentyx Amid Pursuit Of $5 Billion Sales
European Commission (EC) approved Cosentyx for adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA), characterized by chronic back pain.
Read More
Novartis Posts First-Quarter Sales, Profit Beat As COVID-19 Spurs Prescriptions
Sales rose to $12.3 billion from $11.1 billion in the year-ago period, also above the poll average of $12 billion
Read More
Novartis To Sponsor Large Clinical Trial Of HCQ In Hospitalised COVID-19 Patients
Novartis plans to begin enrollment for this study within the next few weeks and is committed to reporting results as soon as possible.
Read More